1. Research progress on thyroid dysfunction induced by immunotherapy for lung cancer
- Author
-
ZHANG Haoting, ZHENG Jing, FU Mengjiao, ZHOU Jianying
- Subjects
immune-related thyroid dysfunction ,immune checkpoint inhibitors ,programmed death-1/programmed death ligand-1 inhibitors ,lung cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Immune checkpoint inhibitors [mainly programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors] have emerged as the most promising therapy in lung cancer treatment. However, clinicians still lack sufficient knowledge about immune-related adverse events. Immune-related thyroid dysfunction (irTD), one of the common immune-related adverse events, can be life-threatening in severe cases. This article discussed the thyroid dysfunction induced by PD-1/PD-L1 inhibitors in the treatment of lung cancer from the aspects of the incidence, pathogenesis, predictive biomarkers and treatment of irTD.
- Published
- 2023
- Full Text
- View/download PDF